Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC us...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/21/5282 |
| _version_ | 1797512719920791552 |
|---|---|
| author | Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura |
| author_facet | Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura |
| author_sort | Yuki Zaizen |
| collection | DOAJ |
| description | Given that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; <i>p</i> = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; <i>p</i> = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; <i>p</i> = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC. |
| first_indexed | 2024-03-10T06:05:41Z |
| format | Article |
| id | doaj.art-8ae148b8cb474f8ead8158db1e124ed8 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T06:05:41Z |
| publishDate | 2021-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-8ae148b8cb474f8ead8158db1e124ed82023-11-22T20:33:01ZengMDPI AGCancers2072-66942021-10-011321528210.3390/cancers13215282Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched AnalysisYuki Zaizen0Masahito Nakano1Kazuta Fukumori2Yoichi Yano3Kota Takaki4Takashi Niizeki5Kotaro Kuwaki6Masaru Fukahori7Takahiko Sakaue8Sohei Yoshimura9Mika Nakazaki10Ryoko Kuromatsu11Shusuke Okamura12Hideki Iwamoto13Shigeo Shimose14Tomotake Shirono15Yu Noda16Naoki Kamachi17Hironori Koga18Takuji Torimura19Division of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, Japan Community Health Care Organization, Saga Central Hospital, Saga 849-8522, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanDivision of Gastroenterology, Department of Medicine, School of Medicine, Kurume University, Kurume 830-0011, JapanGiven that the outcome of hepatic arterial infusion chemotherapy (HAIC) with cisplatin for intrahepatic advanced hepatocellular carcinoma (HCC) is unclear, we aimed to compare prognostic factors for overall survival (OS) following HAIC with cisplatin versus sorafenib for intrahepatic advanced HCC using propensity score-matched analysis. We enrolled 331 patients with intrahepatic advanced HCC who received HAIC with cisplatin (n = 88) or sorafenib (n = 243) between June 2006 and March 2020. No significant difference was observed in OS between HAIC with cisplatin and sorafenib cohorts (median survival time [MST]: 14.0 vs. 12.3 months; <i>p</i> = 0.0721). To reduce confounding effects, 166 patients were selected using propensity score-matched analysis (n = 83 for each treatment). HAIC with cisplatin significantly prolonged OS compared with sorafenib (MST: 15.6 vs. 11.0 months; <i>p</i> = 0.0157). Following stratification according to the Child-Pugh classification, for patients with class A (MST: 24.0 vs. 15.0 months; <i>p</i> = 0.0145), HAIC with cisplatin rather than sorafenib significantly prolonged OS. Our findings suggest that HAIC with cisplatin demonstrates longer prognostic effects than sorafenib in intrahepatic advanced HCC.https://www.mdpi.com/2072-6694/13/21/5282hepatocellular carcinomahepatic arterial infusion chemotherapycisplatinsorafenibmultikinase inhibitorrisk factors |
| spellingShingle | Yuki Zaizen Masahito Nakano Kazuta Fukumori Yoichi Yano Kota Takaki Takashi Niizeki Kotaro Kuwaki Masaru Fukahori Takahiko Sakaue Sohei Yoshimura Mika Nakazaki Ryoko Kuromatsu Shusuke Okamura Hideki Iwamoto Shigeo Shimose Tomotake Shirono Yu Noda Naoki Kamachi Hironori Koga Takuji Torimura Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis Cancers hepatocellular carcinoma hepatic arterial infusion chemotherapy cisplatin sorafenib multikinase inhibitor risk factors |
| title | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
| title_full | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
| title_fullStr | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
| title_full_unstemmed | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
| title_short | Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis |
| title_sort | hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for intrahepatic advanced hepatocellular carcinoma a propensity score matched analysis |
| topic | hepatocellular carcinoma hepatic arterial infusion chemotherapy cisplatin sorafenib multikinase inhibitor risk factors |
| url | https://www.mdpi.com/2072-6694/13/21/5282 |
| work_keys_str_mv | AT yukizaizen hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT masahitonakano hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kazutafukumori hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yoichiyano hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kotatakaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takashiniizeki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT kotarokuwaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT masarufukahori hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takahikosakaue hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT soheiyoshimura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT mikanakazaki hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT ryokokuromatsu hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shusukeokamura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT hidekiiwamoto hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT shigeoshimose hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT tomotakeshirono hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT yunoda hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT naokikamachi hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT hironorikoga hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis AT takujitorimura hepaticarterialinfusionchemotherapywithcisplatinversussorafenibforintrahepaticadvancedhepatocellularcarcinomaapropensityscorematchedanalysis |